Clinical validation of a novel T-cell receptor sequencing assay for identification of recent or prior severe acute respiratory syndrome coronavirus 2 infection
…, TM Snyder, RM Gittelman, T Eerkes… - Clinical Infectious …, 2022 - academic.oup.com
Background While diagnostic, therapeutic, and vaccine development in the coronavirus
disease 2019 (COVID-19) pandemic has proceeded at unprecedented speed, critical gaps in …
disease 2019 (COVID-19) pandemic has proceeded at unprecedented speed, critical gaps in …
[HTML][HTML] Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic …
T Ching, ME Duncan, T Newman-Eerkes… - BMC cancer, 2020 - Springer
Background The clonoSEQ® Assay (Adaptive Biotechnologies Corporation, Seattle, USA)
identifies and tracks unique disease-associated immunoglobulin (Ig) sequences by next-…
identifies and tracks unique disease-associated immunoglobulin (Ig) sequences by next-…
Clinical Validation of a Novel T-cell Receptor Sequencing Assay for Identification of Recent or Prior SARS-CoV-2 Infection (preprint)
ABSTRACT Background While diagnostic, therapeutic, and vaccine development in the
COVID-19 pandemic has proceeded at unprecedented speed and scale, critical gaps remain in …
COVID-19 pandemic has proceeded at unprecedented speed and scale, critical gaps remain in …
MINI01. 02: response and plasma genotyping from phase I/II trial of ensartinib (X-396) in patients (pts) with ALK+ NSCLC: topic: medical oncology
…, JL Gibbons, J Hernandez, T Newman-Eerkes… - Journal of Thoracic …, 2016 - jto.org
Background Ensartinib (X-396) is a novel, potent anaplastic lymphoma kinase (ALK) small
molecule tyrosine kinase inhibitor (TKI) with additional activity against MET, ABL, Axl, EPHA2, …
molecule tyrosine kinase inhibitor (TKI) with additional activity against MET, ABL, Axl, EPHA2, …
144. Clinical Validation and Performance of a T-cell Immunosequencing Assay to Identify Past SARS-CoV-2 Infection
…, TM Snyder, RM Gittelman, T Eerkes… - Open forum …, 2021 - academic.oup.com
Background Our understanding of the SARS-CoV-2 immune response has critical gaps that
are inadequately addressed with available tools. We report the clinical performance of T-…
are inadequately addressed with available tools. We report the clinical performance of T-…
[PDF][PDF] Clinical Validation of a Novel T-Cell Receptor Sequencing Assay for Identification of Recent or Prior Severe Acute Respiratory Syndrome Coronavirus 2 (SARS …
…, JN Dines, TM Snyder, RM Gittelman, T Eerkes… - Health, 2020 - academia.edu
Background. While diagnostic, therapeutic, and vaccine development in the coronavirus
disease 2019 (COVID-19) pandemic has proceeded at unprecedented speed, critical gaps in …
disease 2019 (COVID-19) pandemic has proceeded at unprecedented speed, critical gaps in …
P3. 02a-001 Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK+ NSCLC: Topic: ALK
…, J Gibbons, J Hernandez, T Newman-Eerkes… - Journal of Thoracic …, 2017 - jto.org
Background Ensartinib (X-396) is a novel, potent anaplastic lymphoma kinase (ALK) small
molecule tyrosine kinase inhibitor (TKI) with additional activity against MET, ABL, Axl, EPHA2, …
molecule tyrosine kinase inhibitor (TKI) with additional activity against MET, ABL, Axl, EPHA2, …
143. Use of First-Generation Cephalosporins in Patients with Serious Penicillin Allergies
SE McNeill, S Junco, J Smith, MC Cowart… - Open Forum …, 2021 - academic.oup.com
Background Penicillin allergies have a negative impact on patient outcomes due to utilization
of second-line agents. Newer data suggests cephalosporins are well tolerated in penicillin …
of second-line agents. Newer data suggests cephalosporins are well tolerated in penicillin …
Prince Harry and the honey trap: An argument for criminalizing the nonconsensual use of genetic information
WP Guarnieri - Am. Crim. L. Rev., 2011 - HeinOnline
… In an interview with Wired magazine regarding the passage of GINA, Tera Eerkes, founder
of … Eerkes, is selling that information for commercial advantage.' Since the privacy rules …
of … Eerkes, is selling that information for commercial advantage.' Since the privacy rules …
Review 1:" Clinical Validation of a Novel T-cell Receptor Sequencing Assay for Identification of Recent or Prior SARS-CoV-2 Infection"
C Scagnolari - Rapid Reviews Infectious Diseases, 2022 - rrid.mitpress.mit.edu
ABSTRACTBackgroundWhile diagnostic, therapeutic, and vaccine development in the
COVID-19 pandemic has proceeded at unprecedented speed and scale, critical gaps remain in …
COVID-19 pandemic has proceeded at unprecedented speed and scale, critical gaps remain in …